KDM5-IN-1

KDM5-IN-1 is a potent, selective and orally bioavailable KDM5 inhibitor with an IC50 of 15.1 nM.

Signaling Pathways >> Epigenetics >> Histone Demethylase

Research Areas >> Cancer

IC50: 15.1 nM (KDM5); EC50: 0.34 μM (PC9 H3K4Me3)[1]

KDM5-IN-1 is found to potently inhibit KDM5B and KDM5C isoforms (IC50 of 4.7 and 65.5 nM, respectively). It is significantly less potent against other KDM enzymes (1A, 2B, 3B, 4C, 5A, 6A, 7B), inhibiting KDM4C the strongest with an IC50 of 1.9 μM. KDM5-IN-1 still displays more than 100-fold selectivity for KDM4C vs. KDM5A[1].

When dosed orally in mice at 50 mg/kg twice a day, KDM5-IN-1 shows an unbound maximal plasma concentration Cmax>15-fold over its cell EC50, thereby providing a robust chemical probe for studying KDM5 biological functions in vivo[1].

[1]. Liang J, et al. Lead optimization of a pyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biological studies. Bioorg Med Chem Lett. 2016 Aug 15;26(16):4036-41.

GSK-J4 | QC6352 | GSK2879552 | SP-2509 | CPI-455 | trans-2-Phenylcyclopropylamine hemisulfate salt | 5-Carboxy-8-hydroxyquinoline | ML324 | GSK-LSD1 Dihydrochloride | NCGC00244536 | Daminozide | ORY-1001(trans) | JIB-04 | AS 8351 | KDM5A-IN-1